

RECEIVED
CENTRAL FAX CENTER

NOV 11 2004

from: Diana L. Bush,
Ph.D., Esq.
facsimile: (858) 720-2555
telephone: (858) 720-2885
initials: DLB4

client name: Metabasis Therapeutics, Inc.
date: November 11, 2004
client matter number: 45198.00014CON
pages (with cover): 3

to: U.S. Patent and
Trademark Office
company/office:
facsimile: (703) 872-9306
telephone:

In re Application of:)
Dang, et al.)
Serial No.: 10/615,563) Group Art Unit: 1624
Filed: July 7, 2003) Examiner: Mark L. Berch
For: NOVEL PURINE INHIBITORS OF)
FRUCTOSE-1,6-)
BISPHOSPHATASE)

Attached hereto please find:

(1) Transmittal Form (PTO/SB/21) (1 pg.) and (2) Associate Power of Attorney (1 pg.).

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted (703-872-9306) to the United States Patent and Trademark Office on November 11, 2004.


Helen Lynn

PTO/SB/21 (09-04)


Approved for use through 07/31/2008. OMB 0851-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/615,563	
	Filing Date	July 7, 2003	
	First Named Inventor	Dang et al.	
	Art Unit	1624	
	Examiner Name	Mark L. Berch	
Total Number of Pages in This Submission	2	Attorney Docket Number	45198.00014.CON

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Associate Power of Attorney;
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	PAUL HASTINGS JANOFKY & WALKER LLP		
Signature			
Printed name	Diana L. Bush, Ph.D., Esq.		
Date	11/11/04	Reg. No.	51,109

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name	Helen Lynn	Date	11/11/04

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

American LegalNet, Inc.
www.USCourtForms.com

Patent
45198.00014.CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Dang et al.

Serial No.: 10/615,563

Filed: July 7, 2003

Title: NOVEL PURINE INHIBITORS OF
FRUCTOSE-1,6-BISPHOSPHATASE

Group Art Unit: 1624

Examiner: Mark L. Berch.

RECEIVED
CENTRAL FAX CENTER

NOV 11 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

ASSOCIATE POWER OF ATTORNEY

Dear Sir:

The undersigned attorney in this application hereby appoints JOHN M. LUCAS, Ph.D., J.D., Registration No. 43,373, of Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, Bldg. 300, San Diego, California 92121, as her associate attorney, to transact all business in the U.S. Patent and Trademark Office in connection with the above-identified application.

Respectfully Submitted,

Date:

11/11/04

By:

Diana L. Bush

Diana L. Bush, Ph.D., Esq.
Reg. No. 51,109

PAUL, HASTINGS, JANOFSKY & WALKER LLP
P.O. Box 91902
San Diego, CA 92191-9092
Phone: (858) 720-2500
Fax: (858) 720-2555

SAN/102486.1